CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co (GBIO). (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune ...
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results